A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

To join this study, participants generally need to be in good health. Your doctor will carry out medical checks to make sure you're suitable. You'll also need to agree to use contraception methods described in the study rules if they apply to you.

Key requirements for the eye being studied include having 'wet' Age-related Macular Degeneration (nAMD) for the first time – meaning you haven't received previous treatment for it. Your doctor will confirm this based on scans of your eye. Your vision in the study eye also needs to be within a certain range (between 20/25 and 20/320 on a standard eye chart).

There are reasons you might not be able to join. For example, if your nAMD is caused by something other than age-related issues, or if you have certain other eye problems like bleeding in the eye or a history of eye inflammation. If you've previously had injections or treatments for other retinal conditions in the study eye, you generally won't be able to participate. Also, if your other eye (the non-study eye) has very poor vision or is not present, you might not be eligible.

If you join this study, it will last for 100 weeks, which is almost two years. You'll receive injections of faricimab into your study eye. The aim is to see if these injections can be given as infrequently as every 24 weeks (about every six months), but the exact schedule might vary depending on your individual response. Throughout the study, you'll have regular visits to the clinic for eye exams, vision tests, and scans of your eye to monitor your condition and how you're responding to the treatment. These visits will help doctors assess the effectiveness and safety of faricimab. All procedures and examinations will be clearly explained to you.